TRUMF
Terumo Corporation
OTC Markets OTCPKUSDEQUITY
DELAYED
Last price
16.48
■ 0.00 (0.00%)
MARKET · —
Price
Too many bars for candle bodies at this width — showing high/low range per bar. Zoom in or pick a shorter range.
Open
16.48
Prev close
16.48
Day high
15.06
Day low
15.06
Volume
56
Market cap
—
P/E (TTM)
—
52W range
11.49 – 20.00
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Trailing performance
Returnvs SPY
1W
-3.12%
-1.7%
1M
+17.71%
+14.0%
3M
+42.07%
+39.0%
6M
+30.79%
+19.7%
YTD
+25.13%
+12.8%
1Y
-9.55%
-29.5%
3Y
+12.92%
-61.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Total revenue | $1.13T | $1.04T | $921.86B | $820.21B | +9.2% |
| Operating revenue | $1.13T | $1.04T | $921.86B | $820.21B | +9.2% |
| Cost of revenue | $537.20B | $475.50B | $442.69B | $402.84B | +13.0% |
| Gross profit | $594.67B | $560.67B | $479.17B | $417.37B | +6.1% |
| Selling, general & admin | $409.94B | $381.65B | $344.98B | $299.86B | +7.4% |
| Total operating expense | $418.35B | $403.00B | $339.08B | $300.04B | +3.8% |
| Operating income | $176.32B | $157.67B | $140.09B | $117.33B | +11.8% |
| Net interest income | $2.96B | -$2.62B | $754.00M | -$1.37B | +212.9% |
| Pre-tax income | $178.25B | $154.57B | $140.83B | $116.14B | +15.3% |
| Tax provision | $42.34B | $37.59B | $34.45B | $26.81B | +12.6% |
| Net income | $135.91B | $116.98B | $106.37B | $89.33B | +16.2% |
| Net income to common | $135.91B | $116.98B | $106.37B | $89.33B | +16.2% |
| Basic EPS | 92.14 | 79.01 | 71.50 | 59.50 | +16.6% |
| Diluted EPS | 92.12 | 78.99 | 71.47 | 59.48 | +16.6% |
| EBIT | $181.54B | $160.82B | $143.60B | $120.15B | +12.9% |
| EBITDA | $276.92B | $246.27B | $220.35B | $190.39B | +12.4% |
| Basic shares | 1.48B | 1.48B | 1.49B | 1.49B | -0.4% |
| Diluted shares | 1.48B | 1.48B | 1.49B | 1.50B | -0.4% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $280.49B | $221.87B | $204.88B | $187.32B | +26.4% |
| Cash & short-term investments | $280.73B | $222.26B | $231.04B | $187.43B | +26.3% |
| Accounts receivable | $214.93B | $176.85B | $178.71B | $150.63B | +21.5% |
| Inventory | $335.63B | $294.38B | $286.60B | $249.62B | +14.0% |
| Total current assets | $861.04B | $723.50B | $722.12B | $611.40B | +19.0% |
| Property, plant & equipment | $506.48B | $431.08B | $415.85B | $370.87B | +17.5% |
| Goodwill & intangibles | $803.41B | $545.24B | $588.23B | $538.21B | +47.3% |
| Total assets | $2.31T | $1.83T | $1.83T | $1.60T | +26.5% |
| Total current liabilities | $540.73B | $240.97B | $379.15B | $218.00B | +124.4% |
| Current debt | $279.89B | $15.00B | $156.87B | $11.22B | +1,765.9% |
| Long-term debt | $99.91B | $159.84B | $74.98B | $220.71B | -37.5% |
| Total debt | $379.80B | $174.84B | $231.85B | $231.94B | +117.2% |
| Total liabilities | $727.73B | $459.86B | $504.31B | $491.16B | +58.2% |
| Retained earnings | $1.12T | $1.02T | $954.68B | $874.27B | +9.9% |
| Shareholder equity | $1.58T | $1.37T | $1.33T | $1.11T | +15.8% |
| Working capital | $320.31B | $482.53B | $342.96B | $393.39B | -33.6% |
| Net tangible assets | $781.10B | $823.29B | $738.87B | $572.85B | -5.1% |
| Shares issued | 1.48B | 1.48B | 1.49B | 1.50B | 0.0% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Net income | $178.25B | $154.57B | $140.83B | $116.14B | +15.3% |
| Depreciation & amortisation | $95.38B | $85.45B | $76.75B | $70.24B | +11.6% |
| Change in working capital | -$27.43B | -$14.26B | -$29.86B | -$35.84B | -92.3% |
| Operating cash flow | $230.85B | $210.80B | $146.33B | $117.54B | +9.5% |
| Capital expenditure | -$101.96B | -$82.36B | -$78.77B | -$72.17B | -23.8% |
| Investing cash flow | -$344.10B | -$82.48B | -$81.47B | -$59.12B | -317.2% |
| Share buybacks | -$1.00M | -$30.05B | -$11.11B | -$50.09B | +100.0% |
| Dividends paid | -$41.29B | -$35.62B | -$32.01B | -$27.90B | -15.9% |
| Financing cash flow | $155.50B | -$108.77B | -$62.08B | -$86.56B | +243.0% |
| Free cash flow | $128.89B | $128.44B | $67.56B | $45.36B | +0.4% |
| End cash position | $280.49B | $221.87B | $204.88B | $187.32B | +26.4% |
| Line item | 2026-06-30 | 2025-06-30 | YoY |
|---|---|---|---|
| Basic EPS | 47.74 | 28.37 | +68.3% |
| Diluted EPS | 47.73 | — | — |
| Basic shares | 1.48B | — | — |
| Diluted shares | 1.48B | — | — |
| Line item | 2026-03-31 | 2025-09-30 | 2025-03-31 | YoY |
|---|---|---|---|---|
| Cash & equivalents | $280.49B | $217.16B | $221.87B | +29.2% |
| Cash & short-term investments | $280.73B | $217.29B | $222.26B | +29.2% |
| Accounts receivable | $214.93B | $188.22B | $176.85B | +14.2% |
| Inventory | $335.63B | $311.91B | $294.38B | +7.6% |
| Total current assets | $861.04B | $744.08B | $723.50B | +15.7% |
| Property, plant & equipment | $506.48B | $471.09B | $431.08B | +7.5% |
| Goodwill & intangibles | $803.41B | $543.62B | $545.24B | +47.8% |
| Total assets | $2.31T | $1.89T | $1.83T | +22.0% |
| Total current liabilities | $540.73B | $296.30B | $240.97B | +82.5% |
| Current debt | $279.89B | $59.99B | $15.00B | +366.6% |
| Long-term debt | $99.91B | $99.89B | $159.84B | +0.0% |
| Total debt | $379.80B | $159.87B | $174.84B | +137.6% |
| Total liabilities | $727.73B | $457.29B | $459.86B | +59.1% |
| Retained earnings | $1.12T | $1.07T | $1.02T | +4.0% |
| Shareholder equity | $1.58T | $1.44T | $1.37T | +10.2% |
| Working capital | $320.31B | $447.78B | $482.53B | -28.5% |
| Net tangible assets | $781.10B | $893.92B | $823.29B | -12.6% |
| Shares issued | 1.48B | 1.48B | 1.48B | 0.0% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
15.51
+6.26% from price
SMA 20
14.61
+12.78% from price
SMA 50
13.98
+17.91% from price
SMA 100
13.48
+22.25% from price
SMA 200
13.78
+19.61% from price
EMA 12
15.59
+5.68% from price
EMA 26
14.77
+11.59% from price
EMA 50
14.21
+15.94% from price
RSI (14)
67.0
Neutral
MACD (12,26,9)
0.83
Hist 0.27
ATR (14)
0.50
3.02% of price
Realised vol 30D
90.5%
Annualised
Bollinger upper
17.54
20, 2σ
Bollinger lower
11.69
20, 2σ
50 / 200 cross
Golden
13.98 vs 13.78
Trend bias
Above 200
+19.61%
Risk profile
Beta vs SPY
-0.66
Less volatile than market
Correlation to SPY
-0.08
Largely independent
Realised vol 30D
90.5%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-41.4%
Peak to trough
Max drawdown 5Y
-54.0%
Peak to trough
ATR 14
0.50
3.02% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
NICE Supports Routine NHS Funding and Access to Ex-Situ Machine Perfusion in a Major Step Forward for Liver Transplantation
GlobeNewswire · 2d ago
Terumo Corp (TRUMF) (Q1 2027) Earnings Call Highlights: Record Revenue and Profit Surge on ...
GuruFocus.com · 12d ago
Global Apheresis Market to Reach USD 4.41 Billion by 2031, Driven by Plasma-Based Therapies and Automated Technologies
GlobeNewswire · 29d ago
Zacks Industry Outlook Highlights Terumo, QuidelOrtho, Lumexa Imaging and Brainsway
Zacks · 33d ago
4 Medical Products Stocks Poised to Win Despite Industry Headwinds
Zacks · 33d ago
IceCure Highlights New Peer-Reviewed Journal Article in Leading Surgery Journal, Demonstrating Cryoablation's Advantages Over Radiofrequency Ablation for Early-Stage Breast Cancer
PR Newswire · 60d ago
Terumo (TSE:4543) Valuation Check After Strong 2026 Earnings And Sharp Share Price Rebound
Simply Wall St. · 90d ago
Why Terumo (TSE:4543) Is Up 24.5% After Stronger Full-Year Earnings Lift Profitability - And What's Next
Simply Wall St. · 90d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.